Cargando…
Trial watch: Monoclonal antibodies in cancer therapy
During the past 20 years, dozens—if not hundreds—of monoclonal antibodies have been developed and characterized for their capacity to mediate antineoplastic effects, either as they activate/enhance tumor-specific immune responses, either as they interrupt cancer cell-intrinsic signal transduction ca...
Autores principales: | Vacchelli, Erika, Eggermont, Alexander, Galon, Jérôme, Sautès-Fridman, Catherine, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583934/ https://www.ncbi.nlm.nih.gov/pubmed/23482847 http://dx.doi.org/10.4161/onci.22789 |
Ejemplares similares
-
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2014) -
Trial watch: Oncolytic viruses for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013) -
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
por: Aranda, Fernando, et al.
Publicado: (2014) -
Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013) -
Trial Watch: Peptide vaccines in cancer therapy
por: Aranda, Fernando, et al.
Publicado: (2013)